Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Raw Materials: 2010-2019

Historic Raw Materials for UNITED THERAPEUTICS (UTHR) over the last 10 years, with Dec 2019 value amounting to $21.1 million.

  • UNITED THERAPEUTICS's Raw Materials fell 9.87% to $20.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $20.1 million, marking a year-over-year decrease of 9.87%. This contributed to the annual value of $21.1 million for FY2019, which is 13.17% down from last year.
  • According to the latest figures from FY2019, UNITED THERAPEUTICS's Raw Materials is $21.1 million, which was down 13.17% from $24.3 million recorded in FY2018.
  • UNITED THERAPEUTICS's Raw Materials' 5-year high stood at $27.9 million during FY2017, with a 5-year trough of $21.1 million in FY2019.
  • Over the past 3 years, UNITED THERAPEUTICS's median Raw Materials value was $24.3 million (recorded in 2018), while the average stood at $24.4 million.
  • In the last 5 years, UNITED THERAPEUTICS's Raw Materials increased by 9.96% in 2016 and then declined by 13.17% in 2019.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Raw Materials stood at $23.1 million in 2015, then climbed by 9.96% to $25.4 million in 2016, then climbed by 9.84% to $27.9 million in 2017, then decreased by 12.90% to $24.3 million in 2018, then decreased by 13.17% to $21.1 million in 2019.